02:26 AM EDT, 10/27/2026 (MT Newswires) -- Roche (RO.SW) obtained a CE Mark for its cobas smart e immunoanalyser, a new immunoassay testing platform. The new platform offers a planned menu of over 100 high-medical-value assays across critical diseases, with reaction times of 18 minutes or less for more than 90% of tests, the Swiss drugmaker said Tuesday.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.